

EDWARDS LIFESCIENCES CORPORATION
Impact of Transcatheter Heart Valve Therapy (THV) Sales Return Reserve

(\$ in millions)

QTD	Q4 2014 GAAP Sales	Non-GAAP Adjustments		Q4 2014 Non-GAAP Sales
		Sales Return Reserve Usage	New Sales Return Reserve, Net	
United States	\$ 286.6	\$ (3.1)	\$ -	\$ 283.5
Europe	193.5	(0.7)	-	192.8
ROW	137.9	-	-	137.9
Total Sales	\$ 618.0	\$ (3.8)	\$ -	\$ 614.2
THV United States	\$ 129.5	\$ (3.1)	\$ -	\$ 126.4

YTD	Q4 YTD 2014 GAAP Sales	Non-GAAP Adjustments		Q4 YTD 2014 Non-GAAP Sales
		Sales Return Reserve Usage	New Sales Return Reserve, Net	
United States	\$ 1,047.3	\$ (46.2)	\$ 38.7	\$ 1,039.8
Europe	744.5	(8.0)	1.4	737.9
ROW	531.1	-	-	531.1
Total Sales	\$ 2,322.9	\$ (54.2)	\$ 40.1	\$ 2,308.8
THV United States	\$ 429.6	\$ (46.2)	\$ 38.7	\$ 422.1

Cumulative Sales Return Reserve

Q4 2013 Initial Sales Return Reserve	\$ 14.1
Q1 2014 Additional Reserve, Net	6.1
Q2 2014 Additional Reserve, Net	2.0
Q3 2014 Reserve Reversal, Net	(18.4)
Q4 2014 Reserve Reversal, Net	(3.8)
Net Sales Return Reserve as of December 31, 2014	\$ -